The usefulness of arbekacin compared to vancomycin

The bacteriological efficacy response (improved, arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical efficacy response (improved, arbekacin vs. vancomycin; 65.3% vs. 76.1%) were not statistically different between the two groups. The complication rate was significantly higher in the vancomycin g...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2012-07, Vol.31 (7), p.1663-1666
Main Authors: Hwang, J.-H., Lee, J.-H., Moon, M.-K., Kim, J.-S., Won, K.-S., Lee, C.-S.
Format: Article
Language:English
Subjects:
Adult
Anti-Bacterial Agents - administration & dosage
Antibacterial agents
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Case-Control Studies
Chi-square test
Dibekacin - administration & dosage
Dibekacin - analogs & derivatives
Female
Fever
Hospitals
Humans
Infectious diseases
Internal Medicine
Male
Medical Microbiology
Medical sciences
Methicillin-Resistant Staphylococcus aureus - drug effects
Methicillin-Resistant Staphylococcus aureus - isolation & purification
Middle Aged
Pharmacology. Drug treatments
Preventive medicine
Retrospective Studies
Staphylococcal Infections - complications
Staphylococcal Infections - drug therapy
Staphylococcal Infections - microbiology
Staphylococcus infections
Treatment Outcome
Vancomycin - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The bacteriological efficacy response (improved, arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical efficacy response (improved, arbekacin vs. vancomycin; 65.3% vs. 76.1%) were not statistically different between the two groups. The complication rate was significantly higher in the vancomycin group (32.9%) compared to the arbekacin group (15.1%) ( p  = 0.019). Arbekacin was not inferior to vancomycin, and it could be a good alternative drug for vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) treatment.
ISSN:0934-9723
1435-4373
DOI:10.1007/s10096-011-1490-9